外周 T 细胞淋巴瘤 (PTCL) 是非霍奇金淋巴瘤的一种侵袭性形式。 PTCL 有多种亚型，其中最常见的是未另行指定的 PTCL (PTCL-NOS)。这种亚型通常复发率很高。做出准确的诊断需要分子遗传学分析、组织病理学检查和免疫表型分析。 PTCL 的治疗传统上从 CHOP 方案（环磷酰胺、阿霉素、长春新碱和泼尼松）开始。我们介绍了一名 PTCL-NOS 患者的病例，尽管采用了多种治疗方案（包括传统的治疗药物和新型治疗药物），但病情仍出现进展，最终使用基于 TET2 突变选择的氮胞苷取得了良好的效果。该病例提出了未来研究阿扎胞苷对该患者群体的疗效，并进一步探索表观遗传疗法在 PTCL 中的更广泛用途。版权所有 © 2024，Le 等人。

Peripheral T-cell lymphomas (PTCLs) are an aggressive form of non-Hodgkin lymphomas. PTCLs have multiple subtypes, with PTCL not otherwise specified (PTCL-NOS) being the most common. This subtype usually has a high rate of relapse. Making an accurate diagnosis requires molecular genetic analyses, histopathological examination, and immunophenotyping. Treatment for PTCL traditionally starts with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). We present a case of a patient with PTCL-NOS who progressed despite multiple treatment regimens, including both traditional and novel therapeutic agents, and finally achieved good results with azacytidine, selected based on a TET2 mutation. This case proposes future research into Azacytidine's efficacy in this patient population and further exploration of the broader utility of epigenetic therapies in PTCL.Copyright © 2024, Le et al.